BK Virus Infection Market Summary

• The BKV infection Therapeutics Market Size across the 7MM is anticipated to be ~USD 35 million in 2025, representing a CAGR of ~45%. The BK Virus Infection Market expansion is expected to be driven by the anticipated entry of disease-specific therapies for BK DNAemia/BKPyVAN and BKHC, increasing diagnosis.
• The leading BK Virus Infection Companies include AlloVir, Amplyx Pharmaceuticals, SL VAXiGEN, Hybridize Therapeutics, and others.

BK Virus Infection Market & Epidemiology Insights

• BK virus infection represents a concentrated, high-value opportunity, primarily driven by BK virus-associated nephropathy (BKVAN) in kidney transplant recipients and BK virus-associated hemorrhagic cystitis (BKHC) in HSCT recipients, with commercial success dependent on targeting high-risk patients and demonstrating meaningful renal or clinical outcomes.
• Although BKPyV is also clinically relevant in Hematopoietic Stem Cell Transplantation (HSCT), particularly in BKPyV-associated hemorrhagic cystitis, the most mature epidemiological and therapeutic evidence base remains concentrated in kidney transplantation.
• The diagnosed prevalent cases of BKV infection in the US are estimated at ~4,300 cases in 2025, representing the largest patient share among the 7MM. The higher diagnosed burden in the US may reflect its large transplant population, greater availability of routine BKV PCR-based surveillance, and broader recognition of BKV infection in immunocompromised patients, particularly kidney transplant recipients.
• Among classification-specific BKVAN cases in kidney transplant recipients across EU4 and the UK, Class 2 represented the largest segment in 2025, with ~480 cases, followed by Class 1 at ~300 cases and Class 3 at ~100 cases. This distribution highlights Class 2 as the predominant histopathological grade within the diagnosed BKVAN population in the region.
• The National Kidney Federation reports that ~20% of kidney transplant recipients develop BKV DNAemia, of whom around 25% progress to BK nephropathy (BKVAN); accordingly, a 25% progression rate was applied to the estimated BKV DNAemia/viremia population to derive BKVAN cases.
• In Japan, Grade 2 emerged as the leading severity level for HSCT-associated BKHC cases, accounting for ~400 cases in 2025, followed by Grade 3 at ~300 cases, while Grade 1 and Grade 4 remained equal at ~110 cases each.
• The current BK Virus Infection Treatment Market is dominated by off-label, non-specific approaches, with IVIG, cidofovir, leflunomide, and fluoroquinolones (ciprofloxacin/levofloxacin) forming the core treatment landscape for both BKVAN and BKHC. The absence of an approved, virus-directed therapy creates a highly fragmented market with substantial unmet need.

Request to unlock the sample page of the "BKV Infection Treatment Market"

BK Virus Infection Market Size and Forecast

Key Factors Driving the Growth of the BK Virus Infection Market

• Rising Number of Organ Transplant Procedures

The increasing number of kidney and other solid-organ transplant procedures is contributing to the growing patient population at risk of BK virus reactivation, particularly among immunosuppressed individuals.

• Growing Prevalence of BK Virus-Associated Nephropathy

The rising recognition of BK virus-associated nephropathy (BKVAN) among kidney transplant recipients is increasing the demand for effective diagnostic, monitoring, and therapeutic solutions.

• Increasing Demand for Advanced Diagnostic Technologies

Growing adoption of quantitative PCR testing and other molecular diagnostic techniques is supporting early detection, viral load monitoring, and timely management of BK virus infections.

• High Unmet Need for Targeted Antiviral Therapies

The limited availability of specifically approved antiviral treatments for BK virus infection is encouraging pharmaceutical and biotechnology companies to explore novel antiviral agents and immunotherapeutic approaches.

• Growing Research and Development Activities

Increasing clinical research into BK virus-specific T-cell therapies, antiviral candidates, and immune-based treatment strategies is expanding the market pipeline and creating new opportunities for therapeutic development.

DelveInsight's ‘BK Virus Infection Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of BK virus infection, historical and forecasted epidemiology, as well as the BK virus infection market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The BK virus infection market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, BK virus infection patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022–2036) across the 7MM regions. The report highlights key unmet medical needs in BK virus infection and maps the competitive and clinical landscape to uncover high value opportunities, providing a clear outlook on future market growth potential.

BK Virus Infection Disease Understanding

BK Virus Infection Overview

BK virus (BKPyV), also known as a human polyomavirus, is a common virus that is typically acquired during childhood. Primary infection is usually asymptomatic or causes mild cold-like symptoms. After the initial infection, the virus remains latent for life in the kidneys and the epithelial lining of the ureters and urinary bladder.

In healthy individuals, the immune system generally keeps the virus in a dormant state. However, when immune function is suppressed, BKV may reactivate and cause clinically significant infection. Reactivation occurs most commonly in kidney transplant recipients, who require long-term immunosuppressive therapy to prevent graft rejection. Active BKV infection can involve the kidneys, ureters, and bladder and may lead to renal injury.

BK Virus Infection Diagnosis

The diagnosis of BKV infection relies on a combination of complementary laboratory and histopathological techniques, selected based on the clinical setting, the urgency of evaluation, and the available diagnostic infrastructure.

Initial assessment typically includes quantitative polymerase chain reaction (PCR) testing for BK viral DNA in urine and plasma, with viruria serving as an early marker of viral reactivation and persistent viremia indicating an increased risk of BKVAN.

Further details are provided in the report...

BK Virus Infection Treatment Landscape

Overall, the BK virus infection treatment landscape remains highly fragmented, with no single therapy delivering consistent, long-term viral control or protection against graft dysfunction across patients. Despite broad use of off-label antiviral and immunosuppression-modulating strategies, real-world experience indicates that many patients remain undertreated, cycle through multiple regimens, or discontinue therapy due to limited efficacy, tolerability concerns, or viremia recurrence.

The complete absence of any FDA, EMA, PMDA, or MHRA-approved drug specifically for BK virus infection sustains this fragmentation and continues to drive demand for simpler, more durable, and biologically targeted approaches that can move beyond cyclic symptomatic management.

DelveInsight anticipates changes in the treatment landscape for BK virus infection over the coming years, driven by emerging therapy Potravitug from Ipsen/ Memo Therapeutics, which is projected to enter the market and has the potential to significantly influence future treatment strategies.

Further details related to country-based variations are provided in the report...

BK Virus Infection Unmet Needs

The section “unmet needs of BK virus infection” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Reliance on immunosuppression reduction leaves a fundamental treatment gap
2. Viral replication is common, but clinically meaningful disease remains difficult to predict and intercept
3. Current management can control the virus at the cost of increased immunological risk
4. Epidemiological and clinical evidence remains disproportionately concentrated in kidney transplantation
5. Epidemiological estimates remain heterogeneous, limiting precise assessment of the addressable population

and others…

Note: Comprehensive unmet needs insights in BK virus infection and their strategic implications are provided in the full report.

BK Virus Infection Epidemiology Insights in the 7MM

The BK Virus Infection epidemiology section provides insights about the historical and current BK Virus Infection patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the BK Virus Infection market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings from BK Virus Infection Epidemiological Analysis and Forecast

• The total number of BKVAN cases across the 7MM is expected to increase from ~4000 cases in 2025, primarily reflecting the growing kidney transplant population, continued exposure to immunosuppressive therapy, and improved screening and surveillance for BKPyV DNAemia among kidney transplant recipients.
• The diagnosed prevalent cases of BKV infection in the US are estimated at 4,300 cases in 2025, representing the largest patient share among the 7MM.
• In 2025, Japan was estimated to have approximately 925 cases of BKHC, reflecting the addressable patient population within the country’s allogeneic HSCT setting.
• Class 2 BKVAN represents the predominant disease segment, accounting for approximately 55% of total BKVAN cases across the 7MM, highlighting this subgroup as a key focus of the addressable patient population and a potentially important target for emerging disease-specific therapies.
• Among grade-specific BKHC cases in the US, Grade 2 was the predominant category, accounting for approximately 44% of cases, followed by Grade 3, indicating that a substantial proportion of patients present with moderate-to-severe disease.

BK Virus Infection Epidemiology Segmentation in the 7MM

• Total Cases of BK Viremia in Kidney Transplant Patients
• Total Cases of BKVAN
• Classification-specific Cases of BKVAN
• Type-specific HSCT Cases
• Total Cases of BKHC
• Grade-specific Cases of BKHC
• Treated Cases of BKVAN in kidney transplant
• Treated Cases for BK-HC

BK Virus Infection Market Recent Breakthroughs and Developments

• In June 2026, Memo Therapeutics presented the complete Phase II SAFE KIDNEY II dataset at the American Transplant Congress 2026, reporting sustained reductions in BKPyV viral load and resolution of biopsy-proven BKPyV-associated nephropathy through week 38.
• In April 2026, Asahi Kasei completed its acquisition of AiCuris, bringing AIC468 into its pharmaceutical pipeline with deal value of USD 920 million. AIC468 had completed Phase I and was being developed for BKV infection in kidney transplant and hematopoietic stem cell transplant recipients, with Asahi Kasei planning to advance its development through its US subsidiary Veloxis Pharmaceuticals.

BK Virus Infection Drug Analysis & Competitive Landscape

The BK virus infection drug chapter provides a detailed, market-focused review of emerging pipeline across mid and late Phase BK virus infection clinical trials.

It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming Key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the BK virus infection treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the BK virus infection therapeutics market.

BK Virus Infection Pipeline Analysis

• Potravitug: Ipsen/ Memo Therapeutics

Potravitug is an investigational fully human IgG1-kappa monoclonal antibody targeting the VP1 major capsid protein of BK polyomavirus (BKPyV). By binding to VP1, Potravitug blocks viral attachment and entry into host cells, thereby neutralizing BKPyV across all four known serotypes.

The therapy is being developed as a targeted treatment for BKPyV infection in kidney transplant recipients, with the potential to reduce viral replication while avoiding the need for extensive reduction of immunosuppression.

Currently in Phase II/III reporting sustained reductions in BKPyV viral load and resolution of biopsy-proven BKPyV-associated nephropathy through Week 38.

• The US FDA and European Commission granted Fast Track and Orphan Drug designations, respectively, to potravitug (AntiBKV) for the treatment of BKPyV infection in kidney/renal transplant recipients, underscoring the significant unmet need and absence of approved targeted therapies for this population.

BK Virus Infection Market Outlook

The BK Virus Infection Market Outlook remains encouraging, driven by its rare disease designation, high unmet clinical need, and growing awareness leading to earlier diagnosis. Current care is largely symptomatic and centers on modulating immunosuppression, aimed at controlling viral replication and preventing graft injury rather than directly targeting the underlying viral biology.

No drug is specifically approved for BK virus infection in the US (FDA), EU (EMA), UK (MHRA), or Japan (PMDA); pharmacological management relies entirely on off-label use of antiviral agents, immunosuppression reduction strategies, and other regionally accepted supportive approaches.

Overall, in BK virus infection, the launch of targeted therapies, improved diagnosis through advanced neuroimaging and biomarker-based assessments, and increasing disease awareness are expected to drive steady growth in the 7MM BK virus infection market from 2025–2036, with strong commercial implications for emerging pipelines.

Key findings from BK Virus Infection Market Forecast Report

• In 2025, the BK Virus Infection Treatment Market Size in the US was estimated at ~USD 15 million, representing the dominant share of around 55% of the total 7MM market.
• In 2025, EU4 and the UK collectively contributed approximately ~USD 14.5 million to the BK virus infection market, accounting for around 30% of the total 7MM revenues.
• In 2025, Japan accounted for approximately b in BK Virus Infection Therapeutics Market revenues, representing a ~20% share of the total 7MM market.
• A notable recent shift in the treatment landscape is the gradual expansion of the pipeline, with emerging agents such as Potravitug, AIC468, MAU868, LB-DTK-BKV, and LB-DTK-MV. These investigational therapies are anticipated to play a pivotal role in transforming future management approaches by targeting underlying BK virus infection.

Further details will be provided in the report...

BK Virus Infection Companies

• Ipsen
• Memo Therapeutics
• Vera Therapeutics
• LucasBio
• SymBio Pharmaceuticals, and others

BK Virus Infection Drug Class/Insights into Leading Emerging Therapies (2022–2036 Forecast)

The BK Virus Infection Treatment landscape remains highly limited and is driven primarily by immune modulation rather than direct antiviral therapy. In kidney transplantation, the standard approach is stepwise reduction or modification of immunosuppressive therapy. In HSCT recipients with BKPyV-HC, management is predominantly supportive, including hydration, analgesia, bladder irrigation, transfusion support, and urologic intervention when required.

Off-label and investigational approaches, including cidofovir, leflunomide, fluoroquinolones, IVIG, and virus-specific T-cell therapy, have been explored for BKPyV infection, but clinical evidence remains limited or inconsistent, and none has established a definitive antiviral standard of care.

Current consensus guidelines recommend reduction of immunosuppression as the primary treatment for persistent BKPyV-DNAemia or BKPyV nephropathy in kidney transplant recipients, while cidofovir, leflunomide, and fluoroquinolones are not recommended for routine use; IVIG may be considered as an adjunct in selected patients. No antiviral therapy is currently approved specifically for BKPyV infection, BKPyV-DNAemia, or BKPyV nephropathy.

Intravenous immunoglobulin (IVIG)

IVIG has been investigated as an adjunctive treatment for BKPyV infection because pooled immunoglobulin preparations contain high titers of BKPyV-neutralizing antibodies and may provide immunomodulatory effects.

Cidofovir:

Cidofovir has demonstrated in vitro activity against BKPyV and has historically been used off-label in patients with persistent or severe infection.

Leflunomide:

Leflunomide has historically been used off-label in BKVAN because its active metabolite has demonstrated potential anti-BKPyV activity in vitro in addition to its immunosuppressive effects.

Fluoroquinolones:

Fluoroquinolones, including ciprofloxacin and levofloxacin, have been investigated because of their proposed inhibitory effects on BKPyV replication.

BK Virus Infection Drug Uptake

This section focuses on the uptake rate of potential BKV Infection drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the BK virus infection drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

Based on the anticipated uptake rates, potravitug is expected to demonstrate a medium-to-fast uptake trajectory across the 7MM within the BKVAN/BK-DNAemia segment, reflecting its more advanced development stage and the regulatory support it has received through Fast Track and Orphan Drug designations. In contrast, MAU868 and AIC468 are projected to see medium uptake across all markets, consistent with their comparatively earlier positioning and the presence of a competing, more differentiated asset.

Within the BK-HC segment, both LB-DTK-BKV and LB-DTK-MV are similarly expected to achieve medium uptake uniformly across the 7MM. Overall, potravitug is positioned to be the fastest-adopted therapy among these emerging candidates, while the remaining pipeline assets are anticipated to follow a steadier, more gradual uptake pattern as clinical experience and physician familiarity build over time.

Detailed insights of emerging therapies' drug uptake is included in the report...

Industry Experts and Physician Views for BK Virus Infection

To keep up with BK virus infection market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the BK virus infection emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts engaged with 40+ key opinion leaders (KOLs) across major markets to capture country-level insights in BK virus infection Leading centers such as University of California and Royal College of Physicians, among others, were consulted to validate clinical practices, treatment patterns, and emerging therapeutic perspectives.

Their opinion helps understand and validate emerging BK virus infection, therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for Market access, therapy adoption, and pipeline prioritization in BK virus infection.

BKV Infection Report Qualitative Analysis: SWOT and Attribute Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and attribute analysis.

In the SWOT analysis of BK virus infection, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Attribute analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts systematically evaluates promising emerging therapies based on a set of relevant attributes, including safety, efficacy, frequency of administration, route of administration, and order of market entry. Efficacy is assessed primarily through the trial's stated primary and secondary outcome measures, providing a clinically grounded basis for comparing therapeutic potential across candidates.

Safety is evaluated in parallel, with particular emphasis on acceptability, tolerability, and the nature and frequency of adverse events reported during clinical development, as these factors directly influence real-world adoption and patient retention on therapy.

Beyond clinical performance, the scoring framework also incorporates practical and commercial considerations, including the route of administration (which affects convenience and patient preference), order of entry into the market (which shapes competitive positioning relative to existing and pipeline therapies), probability of technical and regulatory success, and the addressable patient pool that each therapy is positioned to serve.

Each of these parameters is assigned a relative weightage reflecting its expected influence on commercial performance and clinical adoption.

Scope of the BK Virus Infection Market Report

• The BK Virus Infection Market Report covers a segment of key events, an executive summary, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the BK Virus Infection epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the BK virus infection Therapeutics Market, historical and forecasted BK Virus Infection Market Size, BK Virus Infection Market Share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The BK Virus Infection Market Report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM BK virus infection Drugs Market.

BK Virus Infection Market Report Insight

• BK Virus Infection Therapeutics Market Size
• BK Virus Infection Patient Population Forecast
• BK Virus Infection Pipeline Analysis
• BK Virus Infection Market Size and Trends
• BK Virus Infection Market Opportunity (Current and forecasted)

BK Virus Infection Market Report Key Strengths

• BK Virus Infection Epidemiology-Based (Epi-based) Bottom-Up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year forecast

BK virus infection Market Outlook (North America, Europe, Asia-Pacific)

• BK Virus Infection Patient Burden Trends (by geography)
• BK Virus Infection Treatment Addressable Market (TAM)
• BK Virus Infection Competitive Landscape
• BK Virus Infection Major Companies Insights
• BK Virus Infection Price Trends and Analogue Assessment
• BK Virus Infection Therapies Drug Adoption/Uptake
• BK Virus Infection Therapies Peak Patient Share Analysis

BK Virus Infection Market Report Assessment

• BK Virus Infection Current Treatment Practices
• BK Virus Infection Unmet Needs
• BK Virus Infection Clinical Development Analysis
• BK Virus Infection Emerging Drugs Product Profiles
• BK Virus Infection Market Attractiveness
• BK Virus Infection Qualitative Analysis (SWOT and Attribute Analysis
• BK Virus Infection Market Drivers
• BK Virus Infection Market Barriers

Key Questions Answered in the BK Virus Infection Market Report

BK Virus Infection Treatment Market Insights

• What was the BK virus infection market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of BK virus infection?
• What are the disease risks, burdens, and unmet needs of BK virus infection? What will be the growth opportunities across the 7MM concerning the BK Virus Infection patient population?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of BK virus infection?
• What are the current guidelines for treating BK virus infection in the US, Europe, and Japan?

Reasons to Buy BK Virus Infection Market Forecast Report

• The BK Virus Infection Market Report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the BK virus infection Drugs Market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/BK Virus Infection Prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the BK Virus Infection Drugs Market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and BK Virus Infection Emerging Therapies under the attribute analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing BK Virus Infection Drugs Market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Stay updated with us for Recent Articles

• BK Virus Infection Market Infographics
• BK Virus Infection Newsletter
• New DelveInsight Blogs